Skip to content
IgG4-RD News logo Newsletter
Newsletter
  • IgG4-RD News on Facebook
  • IgG4-RD News on Instagram
  • IgG4-RD News on X
  • About IgG4-RD
    IgG4-RD overview
    Causes
    Clinical profiles
    Diagnosis
    Symptoms
  • Treatment
    Approved treatments
    • Uplizna
    Experimental treatments
    • Glucocorticoids
    • Obexelimab
    • Rilzabrutinib
  • News
  • Featured topics
    Understanding IgG4-RD
    • IgG4-RD diagnosis
    • Living with IgG4-RD
    • Treating IgG4-RD
    • Condition confusion
    • IgG4-RD and mental health
    • Steroid side effects
    Videos: Confronting complexities
    • Exloring diagnostic challenges
    • Hunting IgG4-RD knowledge
    • Identifying IgG4-RD
    • Understanding the IgG4-RD experience
  • Quizzes
    IgG4-RD basics
    IgG4-RD treatments
  • What can we help you find today?

    • IgG4-RD News on Facebook
    • IgG4-RD News on Instagram
    • IgG4-RD News on X
Featured Articles

NEWS

June 13, 2025 News by Marisa Wexler MS

Subset of immune T-cells may be therapeutic target in IgG4-RD

A specific subset of immune cells known as gamma-delta 2 T-cells plays a key role in the development of immunoglobulin G4-related disease (IgG4-RD), a study reports. Particularly, these cells were found to acquire an immune profile, called T helper 2 (Th2)-like phenotype, to strongly promote the formation of plasma…

Read more
A single person highlighted in red stands out in a crowd in this illustration of rare.
June 6, 2025 News by Marisa Wexler MS

US had over 50K cases of IGG4-RD as of 2024, disease statistics show

More than 50,000 people in the U.S. were living with IgG4-related disease (IgG4-RD) as of 2024, a new report on statistics related to the rare immune disease shows. The report provides IgG4-RD epidemiology data, such as the disease’s occurrence, distribution, and patterns, in the U.S. as well as in…

A risk dashboard shows various indicators with a large dial with a red line just before
June 2, 2025 News by Lindsey Shapiro, PhD

Higher cancer risk possible with IgG4-RD diagnosis, report suggests

People with immunoglobulin G4-related disease (IgG4-RD) may be susceptible to developing multiple cancers and should be carefully monitored, according to a new report from researchers in Turkey. In reviewing previously published reports, the scientists found that people who experienced multiple cancers, or malignancies, tended to be older than those…

Featured Topics

  1. June 2, 2025 by Susie Strachan

    After an IgG4-related disease diagnosis: What to expect

  2. June 2, 2025 by Kristin DeJohn

    Building your IgG4-related disease care team

  3. June 2, 2025 by Agata Boxe

    Condition confusion: Why IgG4-RD is often misdiagnosed

  4. June 2, 2025 by Patricia Weiser

    IgG4-related disease steroid side effects: How to cope

  5. June 2, 2025 by Agata Boxe

    Living with IgG4-RD: How to handle symptoms and flares

  6. June 2, 2025 by Elena Schmidt

    Managing mental health with IgG4-related disease

Swipe left to view more
Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

This field is for validation purposes and should be left unchanged.

Bionews logo Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

  • IgG4-RD News on Facebook
  • IgG4-RD News on Instagram
  • IgG4-RD News on X
Copyright © 2013-2025 All rights reserved.